Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
25%(2 trials)

Phase Distribution

Ph phase_1
3
38%
Ph phase_3
3
38%
Ph phase_4
1
13%

Phase Distribution

3

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 33 (42.9%)
Phase 41 (14.3%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

NCT02411526
completedphase_1

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
completedphase_1

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
completedphase_4

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

NCT00313391
completedphase_3

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02411526Phase 1

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Completed
NCT02186769Phase 1

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

Completed
NCT02091388Phase 1

Bioavailability of LY03004 and Risperdal® Consta®

Completed
NCT00313391Phase 4

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

Completed
NCT00589914Phase 3

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

Completed
NCT00294008

A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

Completed
NCT00132678Phase 3

A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

Completed
NCT00094926Phase 3

A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8